Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children.

Dennehy PH, Reisinger KS, Blatter MM, Veloudis BA.

Pediatrics. 1991 Sep;88(3):604-7.

PMID:
1881743
[PubMed - indexed for MEDLINE]
2.

Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity.

Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, Krishnamurty AT, Chang JT, Adams DJ, Hensley TR, Salter AI, Morgan CA, Duerr AC, De Rosa SC, Aderem A, McElrath MJ.

Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):E3503-12. doi: 10.1073/pnas.1208972109. Epub 2012 Nov 14.

PMID:
23151505
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP).

Goulleret N, Mauvisseau E, Essevaz-Roulet M, Quinlivan M, Breuer J.

Vaccine. 2010 Aug 16;28(36):5878-82. doi: 10.1016/j.vaccine.2010.06.056. Epub 2010 Jun 30.

PMID:
20600487
[PubMed - indexed for MEDLINE]
4.

MK-431 (Merck).

Deacon CF.

Curr Opin Investig Drugs. 2005 Apr;6(4):419-26. Review.

PMID:
15898349
[PubMed - indexed for MEDLINE]
5.

Vioxx, the implosion of Merck, and aftershocks at the FDA.

Horton R.

Lancet. 2004 Dec 4-10;364(9450):1995-6. No abstract available.

PMID:
15582041
[PubMed - indexed for MEDLINE]
6.

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

Sekaly RP.

J Exp Med. 2008 Jan 21;205(1):7-12. doi: 10.1084/jem.20072681. Epub 2008 Jan 14.

PMID:
18195078
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Failing the public health--rofecoxib, Merck, and the FDA.

Topol EJ.

N Engl J Med. 2004 Oct 21;351(17):1707-9. Epub 2004 Oct 6. No abstract available.

PMID:
15470193
[PubMed - indexed for MEDLINE]
Free Article
8.

Profitable gifts: a history of the Merck Mectizan donation program and its implications for international health.

Collins K.

Perspect Biol Med. 2004 Winter;47(1):100-9.

PMID:
15061171
[PubMed - indexed for MEDLINE]
9.

Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans.

Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC.

Nat Med. 2008 Jun;14(6):617-21. doi: 10.1038/nm.f.1759.

PMID:
18535579
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Cilengitide Merck.

Smith JW.

Curr Opin Investig Drugs. 2003 Jun;4(6):741-5. Review.

PMID:
12901235
[PubMed - indexed for MEDLINE]
11.

Varivax (Merck & Co).

Jones T.

Curr Opin Investig Drugs. 2002 Jan;3(1):54-7. Review.

PMID:
12054073
[PubMed - indexed for MEDLINE]
12.

Translating evidence-based interventions into practice: the design and development of the Merck Childhood Asthma Network, Inc. (MCAN).

Viswanathan M, Lux L, Lohr KN, Evans TS, Smith LR, Woodell C, Mansfield C, Darcy N; MCAN Site Investigators, Ohadike YU, Lesch JK, Malveaux FJ.

Health Promot Pract. 2011 Nov;12(6 Suppl 1):9S-19S. doi: 10.1177/1524839911412594.

PMID:
22068366
[PubMed - indexed for MEDLINE]
13.

Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine.

Bernstein HH, Rothstein EP, Watson BM, Reisinger KS, Blatter MM, Wellman CO, Chartrand SA, Cho I, Ngai A, White CJ.

Pediatrics. 1993 Dec;92(6):833-7.

PMID:
8233746
[PubMed - indexed for MEDLINE]
14.

Cetuximab (Imclone/Merck/Bristol-Myers Squibb).

Kies MS, Harari PM.

Curr Opin Investig Drugs. 2002 Jul;3(7):1092-100. Review.

PMID:
12186273
[PubMed - indexed for MEDLINE]
15.

Cross-site evaluation of a comprehensive pediatric asthma project: the Merck Childhood Asthma Network, Inc. (MCAN).

Viswanathan M, Mansfield C, Smith LR, Woodell C, Darcy N, Ohadike YU, Lesch JK, Malveaux FJ.

Health Promot Pract. 2011 Nov;12(6 Suppl 1):20S-33S. doi: 10.1177/1524839911412595.

PMID:
22068358
[PubMed - indexed for MEDLINE]
16.

Modified chickenpox in children immunized with the Oka/Merck varicella vaccine.

Watson BM, Piercy SA, Plotkin SA, Starr SE.

Pediatrics. 1993 Jan;91(1):17-22. Review.

PMID:
8416499
[PubMed - indexed for MEDLINE]
17.

Zoster vaccine live (Oka/Merck).

Robinson DM, Perry CM.

Drugs Aging. 2006;23(6):525-31; discussion 532-3. Review.

PMID:
16872235
[PubMed - indexed for MEDLINE]
18.

Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.

Silber JL, Chan IS, Wang WW, Matthews H, Kuter BJ.

Pediatr Infect Dis J. 2007 Jul;26(7):572-6.

PMID:
17596796
[PubMed - indexed for MEDLINE]
19.

Merck pays $1bn penalty in relation to promotion of rofecoxib.

Tanne JH.

BMJ. 2011 Nov 28;343:d7702. doi: 10.1136/bmj.d7702. No abstract available.

PMID:
22123916
[PubMed - indexed for MEDLINE]
20.

Ezetimibe + simvastatin (Merck/Schering-Plough).

Flores NA.

Curr Opin Investig Drugs. 2004 Sep;5(9):984-92. Review.

PMID:
15503655
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk